LAG3 and melanoma: Hemon et al. highlighted its impact on immune escape and cancer survival, as both sLAG-3 and LAG-3-transfected cells can protect MHC II-positive melanoma cells, but not MHC II-negative cells, from FAS-mediated and drug-induced apoptosis, through promotion of MAPK/Erk and PI3K/Akt survival pathways through the interaction of LAG-3 with MHC II was expressed on melanoma cells [33].